LWANC
RNAM

Laurel Wealth Advisors (North Carolina)’s Avidity Biosciences RNAM Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed -$1K – 597
2022
Q2 		$1K Hold
100
– – ﹤0.01% 606
2022
Q1 		$2K Hold
100
– – ﹤0.01% 596
2021
Q4 		$2K Hold
100
– – ﹤0.01% 599
2021
Q3 		$2K Hold
100
– – ﹤0.01% 608
2021
Q2 		$2K Hold
100
– – ﹤0.01% 685
2021
Q1 		$2K Buy
+100
New +$2.45K ﹤0.01% 620

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s RNAM Position: Q3 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Avidity Biosciences (RNAM) in Q3 2022, closing a stake of 100 shares — an estimated $1K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in RNAM in Q1 2021 and held it in 6 quarters. The position peaked at $2K in Q1 2022. 127 funds tracked by Wall St. Rank hold RNAM as of Q3 2022.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Avidity Biosciences position as of Q3 2022 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 100 Avidity Biosciences shares in Q3 2022, an estimated $1K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Avidity Biosciences in Q1 2021 and held it in 6 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Avidity Biosciences position peaked at $2K in Q1 2022.
  • 127 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2022, filed 15 Nov 2022.